Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
- PMID: 19098898
- PMCID: PMC2895694
- DOI: 10.1038/nbt.1515
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Abstract
Delivery of genes to the brain and spinal cord across the blood-brain barrier (BBB) has not yet been achieved. Here we show that adeno-associated virus (AAV) 9 injected intravenously bypasses the BBB and efficiently targets cells of the central nervous system (CNS). Injection of AAV9-GFP into neonatal mice through the facial vein results in extensive transduction of dorsal root ganglia and motor neurons throughout the spinal cord and widespread transduction of neurons throughout the brain, including the neocortex, hippocampus and cerebellum. In adult mice, tail vein injection of AAV9-GFP leads to robust transduction of astrocytes throughout the entire CNS, with limited neuronal transduction. This approach may enable the development of gene therapies for a range of neurodegenerative diseases, such as spinal muscular atrophy, through targeting of motor neurons, and amyotrophic lateral sclerosis, through targeting of astrocytes. It may also be useful for rapid postnatal genetic manipulations in basic neuroscience studies.
Figures
Comment in
-
Crossing the rubicon.Nat Biotechnol. 2009 Jan;27(1):42-4. doi: 10.1038/nbt0109-42. Nat Biotechnol. 2009. PMID: 19131996 Free PMC article.
-
The neonatal blood-brain barrier is functionally effective, and immaturity does not explain differential targeting of AAV9.Nat Biotechnol. 2009 Sep;27(9):804-5; author reply 805. doi: 10.1038/nbt0909-804. Nat Biotechnol. 2009. PMID: 19741632 No abstract available.
Similar articles
-
Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection.PLoS One. 2017 Dec 15;12(12):e0188830. doi: 10.1371/journal.pone.0188830. eCollection 2017. PLoS One. 2017. PMID: 29244806 Free PMC article.
-
Widespread transduction of astrocytes and neurons in the mouse central nervous system after systemic delivery of a self-complementary AAV-PHP.B vector.Gene Ther. 2018 Apr;25(2):83-92. doi: 10.1038/s41434-018-0005-z. Epub 2018 Mar 9. Gene Ther. 2018. PMID: 29523880
-
Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain.Neurosci Lett. 2018 Feb 5;665:182-188. doi: 10.1016/j.neulet.2017.11.049. Epub 2017 Nov 24. Neurosci Lett. 2018. PMID: 29175632
-
The advent of AAV9 expands applications for brain and spinal cord gene delivery.Expert Opin Biol Ther. 2012 Jun;12(6):757-66. doi: 10.1517/14712598.2012.681463. Epub 2012 Apr 20. Expert Opin Biol Ther. 2012. PMID: 22519910 Free PMC article. Review.
-
Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies.Brain Res. 2020 Jul 15;1739:146832. doi: 10.1016/j.brainres.2020.146832. Epub 2020 Apr 11. Brain Res. 2020. PMID: 32289279 Free PMC article. Review.
Cited by
-
Alternative Anesthesia of Neonatal Mice for Global rAAV Delivery in the Brain With Non-detectable Behavioral Interference in Adults.Front Behav Neurosci. 2020 Jul 14;14:115. doi: 10.3389/fnbeh.2020.00115. eCollection 2020. Front Behav Neurosci. 2020. PMID: 32760256 Free PMC article.
-
Adeno-associated virus-mediated microRNA delivery and therapeutics.Semin Liver Dis. 2015 Feb;35(1):81-8. doi: 10.1055/s-0034-1397352. Epub 2015 Jan 29. Semin Liver Dis. 2015. PMID: 25632938 Free PMC article. Review.
-
Comparative Effectiveness of Intracerebroventricular, Intrathecal, and Intranasal Routes of AAV9 Vector Administration for Genetic Therapy of Neurologic Disease in Murine Mucopolysaccharidosis Type I.Front Mol Neurosci. 2021 May 10;14:618360. doi: 10.3389/fnmol.2021.618360. eCollection 2021. Front Mol Neurosci. 2021. PMID: 34040503 Free PMC article.
-
Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model.Neurobiol Dis. 2015 Oct;82:22-31. doi: 10.1016/j.nbd.2015.04.018. Epub 2015 May 24. Neurobiol Dis. 2015. PMID: 26019056 Free PMC article.
-
Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism.Gene Ther. 2016 Nov;23(11):807-814. doi: 10.1038/gt.2016.62. Epub 2016 Sep 15. Gene Ther. 2016. PMID: 27628693 Free PMC article.
References
-
- Pardridge WM. Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov. 2002;1:131–139. - PubMed
-
- Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003;301:839–842. - PubMed
-
- Azzouz M, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature. 2004;429:413–417. - PubMed
-
- Ralph GS, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med. 2005;11:429–433. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources